Restrictions on interactions between doctors and industry could ultimately hurt patients.
Physician-industry collaboration has led to a diverse array of therapeutic advancements that have benefitted a broad spectrum of patient populations. Evolving regulations, both institutional and governmental, aiming to govern interactions between physicians and pharmaceutical and medical device manufacturers have become increasingly prevalent. Emerging data suggest that restrictions on physician-industry collaboration have the potential to harm patient care by degrading innovation and stifling medical education. The following article reviews the effects of legislation on medical innovation as well as the impact on continuing medical education.